42
Participants
Start Date
May 15, 2018
Primary Completion Date
December 15, 2025
Study Completion Date
October 31, 2026
Azacitidine and Venetoclax
Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
University of Colorado Denver, Aurora
University of Colorado, Denver
OTHER